Dr. Andrew Avarbock, MD
156 William St, 7th Floor, New York, NY 10038 • +1-516-555-2816
Medical Education: Accredited U.S. Medical School (Class of 2000)
What This Doctor Actually Performs: CMS Medicare Utilization & New York Percentiles
NPI #1669649968 • CBSA 35620 • Dermatology
CMS Medicare Part B utilization records credit Dr. Andrew Avarbock (MD, NPI 1669649968) at 156 William St, 7th Floor in New York with 3,702 annual clinical services (272 beneficiaries), corresponding to a -0.08σ regional deviation and upper-quartile active clinical volume (79.61th New York percentile) with sub-specialty concentration in 54 Active CMS HCPCS Codes.
Procedural volume for Dr. Avarbock is led by HCPCS 17000 (Cryotherapy Destruction of Premalignant Actinic Lesion — 1226 annual services, $62–$85 GPCI cash estimate), followed by CPT 99213 (Focused Cutaneous & Dermoscopic Examination, 1118/yr) and CPT 11102 (Tangential Diagnostic Skin Biopsy of Single Lesion, 685/yr).
Uninsured and high-deductible cash patients visiting Dr. Andrew Avarbock in New York (10038) face an estimated $239.00 initial evaluation fee at 156 William St, 7th Floor (hybrid in-clinic and telehealth video consults; 10-minute average reception wait; bedside manner 4.69/5 from 20 verified reports).
Credentialed as an MD specialist with 26 years post-graduation experience since completing medical school at an LCME/COCA institution (2000), Dr. Avarbock coordinates 54 Active CMS HCPCS Codes workups from 156 William St, 7th Floor (+1-516-555-2816).
Compared against New York, NY Dermatology peers
3,702 annual services across 272 beneficiaries
Standard deviations from NY Dermatology mean utilization
Top Billed HCPCS/CPT Procedures & GPCI Self-Pay Cash Benchmarks
| HCPCS | Clinical Procedure Description | Annual Volume | Local Pct | Est. Cash Range |
|---|---|---|---|---|
| 17000 | Cryotherapy Destruction of Premalignant Actinic Lesion | 1,226 | 79.61th | $62 – $85 |
| 99213 | Focused Cutaneous & Dermoscopic Examination | 1,118 | 76.61th | $70 – $95 |
| 11102 | Tangential Diagnostic Skin Biopsy of Single Lesion | 685 | 75.61th | $92 – $125 |
| 11401 | Excision of Benign Cutaneous Lesion (0.6 to 1.0 cm) | 361 | 80.61th | $128 – $176 |
| 99203 | New Patient Full-Body Skin Cancer & Dermatology Evaluation | 216 | 81.61th | $99 – $135 |
| 96372 | Therapeutic Subcutaneous/Intramuscular Injection Administration (54 HCPCS billing breadth) | 96 | 79.61th | $76 – $110 |
Are you Dr. Andrew Avarbock? Embed your Official DotMD Verification Badge (0-JS SVG)
Paste this lightweight SVG snippet onto your clinic bio page in New York, NY:
<a href="https://dotmd.com/doctors/andrew-avarbock-md-new-york-ny-1669649968" title="Dr. Andrew Avarbock, MD - Verified CMS Utilization on DotMD"><img src="https://dotmd.com/badges/npi/1669649968.svg" alt="Dr. Andrew Avarbock Dermatology Badge" width="280" height="72" /></a>
Dr. Andrew Avarbock, MD Fair Cash-Pay & Waiting-Room Scorecard
| Metric | Verified Benchmark | Source |
|---|---|---|
| Dr. Avarbock National Provider Identifier | NPI #1669649968 (MD) | CMS NPPES Registry (10038) |
| Dr. Avarbock New York CMS Volume Rank | 79.61th Pct (3,702 CMS svcs; Z -0.083σ) | CMS Medicare Part B (NY Dermatology) |
| Fair Cash-Pay New-Patient Benchmark | $239.00 (CPT 99204 GPCI Benchmark) | CMS Geographic Practice Cost Index (New York, NY) |
| Waiting-Room Wait Time & Cash Friendliness | $239.00 avg paid • 10 min lobby wait | 20 Anonymous Patient Reports |
| Listens Without Rushing & Modern Protocol Score | 4.69/5 Listening • 4.56/5 Modern Labs | CMS Provider Practice Cohort |
“Waiting Room” Patient Reality Scorecard
Ask our AI Specialists anything about Dr. Andrew Avarbock
Other High-Volume Dermatology Specialists in New York, NY
Ranked strictly by CMS Medicare volumeDr. Avarbock Waiting-Room Q&A & Patient Experience Logs
Anonymous patient-submitted wait times, cash visit fees, and bedside manner discussions in New York, NY.
Share your self-pay visit cost and lobby wait time—no account, email, or IP stored.
Filter Dr. Andrew Avarbock community threads and patient logs by age, biological sex, dosage, and treatment duration.